Table 3 Odds ratios (OR) and 95% confidence intervals (95% CI) of first myocardial infarction after breast cancer diagnosis associated with tumor and treatment characteristics

From: Myocardial infarction risk and tamoxifen therapy for breast cancer

Characteristics

# of cases/# of controls

Univariate OR (95% CI)

Multivariate a OR (95% CI)

Stage at diagnosis

   

 Localised

89/183

1.0 (referent)

1.0 (referent)

 Regional

38/73

1.1 (0.7–1.7)

1.0 (0.6–1.8)

 Distant/unstaged

7/6

2.5 (0.8–8.0)

2.2 (0.6–7.7)

Oestrogen receptor status

 Negative

20/45

1.0 (referent)

1.0 (referent)

 Positive or borderline

86/154

1.3 (0.7–2.4)

1.3 (0.6–2.6)

 Not done

28/63

  

Progesterone receptor status

 Negative

33/73

1.0 (referent)

1.0 (referent)

 Positive or borderline

61/110

1.3 (0.8–2.1)

1.1 (0.6–1.9)

 Not done

40/79

  

Lymph nodes involved

 No

75/155

1.0 (referent)

1.0 (referent)

 Yes

37/71

1.1 (0.7–1.7)

1.0 (0.6–1.9)

 No nodal surgery

22/36

  

Tamoxifen therapy ever b

 No

65/132

1.0 (referent)

1.0 (referent)

 Yes

69/130

1.1 (0.7–1.8)

1.2 (0.7–1.9)

 Duration of use (months)

None

65/132

1.0 (referent)

1.0 (referent)

<24

29/47

1.5 (0.8–2.9)

1.6 (0.8–3.2)

24

35/79

0.9 (0.5–1.5)

0.9 (0.5–1.7)

Unknown

5/4

  

Radiation therapy b

 No

101/223

1.0 (referent)

1.0 (referent)

 Yes

33/39

1.8 (1.1–3.1)

2.0 (1.1–3.5)

 Radiation cumulative dose (rads)c

None

101/223

1.0 (referent)

1.0 (referent)

5000

18/18

2.1 (1.04–4.4)

2.2 (1.01–4.8)

>5000

14/20

1.5 (0.7–3.1)

1.7 (0.7–3.8)

 Radiation side

None

101/223

1.0 (referent)

1.0 (referent)

Right

13/14

2.0 (0.9–4.8)

2.1 (0.8–5.3)

Left

20/25

1.7 (0.9–3.2)

1.9 (0.9–3.9)

Tamoxifen and radiation therapy

 Neither

52/120

1.0 (referent)

1.0 (referent)

 Radiation therapy only

13/12

2.5 (1.02–5.9)

2.9 (1.2–7.5)

 Tamoxifen only

49/103

1.2 (0.7–2.0)

1.3 (0.8–2.3)

 Both

20/27

1.8 (0.9–3.6)

2.0 (0.9–4.4)

Tamoxifen months of use and radiation therapy b

 Neither

52/120

1.0 (referent)

1.0 (referent)

 Radiation therapy only

13/12

2.5 (1.04–6.1)

2.9 (1.1–7.5)

 No radiation therapy

   

Tamoxifen

   

 <24

18/36

1.5 (0.7–3.0)

1.7 (0.8–3.7)

24

26/64

1.0 (0.5–1.8)

1.1 (0.6–2.1)

 Radiation therapy

Tamoxifen

   

 <24

11/11

2.4 (0.9–6.4)

3.2 (1.1–9.1)

24

9/15

1.4 (0.5–3.7)

1.4 (0.5–4.0)

 Tamoxifen months unknown

5/4

  

Chemotherapy

 No

109/218

1.0 (referent)

1.0 (referent)

 Yes

25/44

1.2 (0.6–2.1)

1.2 (0.6–2.3)

  1. a All multivariate models include categorical items for histories of hypertension and diabetes, smoking and a combined item for tamoxifen and radiation treatment.
  2. b In multivariate model, the combined tamoxifen-radiation therapy item was replaced by separate items. For example, the model to examine tamoxifen duration of use included the radiation therapy (yes/no) item.
  3. c Subjects with details unknown removed (one case with matched controls, one control).